Table 2.
Gross and histopathological analysis of TBL in lung and pulmonary lymphoid nodes
| Control | BCG | MTBVAC | |
|---|---|---|---|
| Lung | |||
| Median no. of lobes affected | 3.5 (IQR 1–4) | 1 (IQR 0.8–1)* | 2 (IQR 1–2.5) |
| Median score | 4 (IQR 1–5.8) | 1 (IQR 0.8–1.3)* | 2 (IQR 1–4) |
| No. animals with TBL | 10/11 (83.3%)b | 3/14 (21.4%)* | 8/13 (61.5%) |
| Development stage of granulomas | |||
| I | 0/11 (0%) | 0/14 (0%) | 0/13 (0%) |
| II | 1/11 (9.1%) | 0/14 (0%) | 3/13 (23.1%) |
| III | 2/11 (18.2%) | 0/14 (0%) | 0/13 (0%) |
| IV | 7/11 (63.6%) | 3/14 (21.4%)* | 5/13 (38.5%) |
| Mean of MNGCsa | 7 (± 8.1) | 1.6 (± 3.7)* | 5.1 (± 8) |
| No. animals with satellite granulomas | 0/11 (0%) | 1/14 (7.1%) | 0/13 (0%) |
| Pulmonary LNs | |||
| Median score | 6.5 (IQR 4.3–9.8) | 2 (IQR 1–3.3)* | 2 (IQR 2–4)* |
| No. animals with TBL | 11/11 (100%)b | 8/14 (57.1%)* | 10/13 (76.9%) |
| Development stage of granulomas | |||
| I | 0/11 (0%) | 0/14 (0%) | 1/13 (7.7%) |
| II | 1/11 (9.1%) | 0/14 (0%) | 0/13 (0%) |
| III | 1/11 (9.1%) | 0/14 (0%) | 0/13 (0%) |
| IV | 9/11 (81.8%) | 8/14 (57.1%) | 9/13 (69.2%) |
| Mean of MNGCs | 10.7 (± 6.9) | 3.71 (± 5.52)* | 9.1 (± 11.7) |
| No. animals with satellite granulomas | 5/11 (45.5%) | 1/14 (7.1%) | 4/13 (30.8%) |
IQR, interquartile range; MNGC, multinucleated giant cells; TBL, tuberculous lesion.
* Statistically significant difference with regard to the control group (p ≤ 0.05).
aMNGCs per animal (mean of three microscopic fields 400×).
bLung and pulmonary samples from one animal were not well fixed in formalin and could not be assessed for histopathology.